Alert Fatigue with DDI Software: Potential Solutions

Similar documents
Application of Evidence Based, Patient Specific Drug Interaction Screening

Drug Interactions and Prescribing Errors

To understand the formulary process from the hospital perspective

COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY

12/19/16. Disclosures

AFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June

Drug Interaction Pairs Associated with an Increased likelihood of Hospitalization: A New Look at the Evidence

GUIDANCE FOR LEAPFROG HOSPITAL SURVEY PARTICIPATING HOSPITALS CLINICAL DECISION SUPPORT RELATED TO THE CPOE EVALUATION TOOL

Applying the Goldilocks Principle to Clinical Decision Support. Carla J Maslakowski M.S, M.Ed, RPh

The Case of Libby Zion and Dangerous Drug Interactions

Self Assessment Question 1

Drug Interactions: Let me count the ways

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)

Drug Therapy Following Bariatric Surgery

Understanding the Drug Drug Interaction

Master Class: DOAC Drug Interactions April 20, 2017

Drug Interactions for the Emergency Physician. Lisa Thurgur

Annotation Guidelines

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

Objectives. Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner

Polypharmacy and Common Drug Interactions in Geriatric Patients

July 2011 Medical Update Information

PRESCRIBING ALERT

Risk Factors: An Essential Element for DDI Software

Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System

COMMON DRUG INTERACTIONS: A PRACTICAL REVIEW FOR PHARMACY TECHNICIANS

Zurampic. (lesinurad) New Product Slideshow

Y. W. Francis Lam, Pharm.D. FCCP University of North Texas Health Science Center Grand Round Rx to OTC Switch: Potentials, Challenges, and Initiatives

Drug-drug interactions in the elderly

High-Alert Medications: A Look at the Safe Use of Narcotics. Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP)

Smoking Cessation Pharmacotherapy Guidelines

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

Are We Making Smart Pumps Smarter?

Drug Interactions: Mechanisms and Potential Clinical Outcomes

FREQUENTLY ASKED QUESTIONS

CLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION

Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )

Pain Management A guide for patients

Drug Interactions. Pharmacokinetic DIs 3/3/2014. SCSHP 2014 Annual Meeting

Summary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol)

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin

Today the overuse of opioids is a problem. Many of

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

eview Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP yright t for Sale or Commercial Distribution

Amiodarone Therapy. Exceptional healthcare, personally delivered

Case Study Activity: Strategies to Support the Safe Use of Acetaminophen

High Alert Medications in the long-term care setting. Carrie Allen PharmD, CGP, BCPS, CCHP

CHAPTER II DRUG INDUCED PULMONARY DISEASES. BY J. jayasutha lecturer department of pharmacy practice Srm college of pharmacy SRM UNIVERSITY

Meds and Falls: Keep in Step with your Meds

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly

Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential

A Case Study on Visual Analytics for Optimizing Drug Duplicate Alerts in a Medication Clinical Decision Support System

Who remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?

A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse

MODULE 1: BASIC DRUG KNOWLEDGE

INTELENCE etravirine. What is in this leaflet. Before you take INTELENCE. What INTELENCE is used for. When you must not use it:

PHARMACOTHERAPY IN THE OLDER PERSON NAMIRAH JAMSHED M.B;B.S ASSOCIATE PROFESSOR UTSW MEDICAL CENTER DALLAS

There is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.

Alabama Medicaid DUR Board Meeting Minutes October 22, 2008

90-Day Generic Drug Discount List Treatment Medication Strength Dose Quantity Price Allergy/Cold&Flu Benzonatate 100mg Tablet 42 $15.

12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc.

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

Intelligent Polypharmacy. Professor Colin P Bradley Department of General Practice University College Cork

Summary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol)

Produced by The Kidney Foundation of Canada

Direct Oral Anticoagulants

Special Generic Drug Pricing Program

OBJECTIVES. Key issues in geriatric pharmacology. Effects of age on pharmacokinetics and pharmacodynamics

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA

For further information, please contact BC Women s Sexual Assault Service at Thank-you.

Drug Review Rozerem (ramelteon)

Rifamycins Drug interactions

A clinical guide to managing drugdrug interactions in antiretroviral therapy

Technician Training Tutorial: Safety Considerations with Opioids

Domperidone: Drug Interactions & Cautions (Mayo Clinic)

Adverse Drug Events in the Older Adult Population. Alan Lukazewski, RPh, CDE, CGP Oakwood Lutheran Senior Ministries 1

JEANIE JARAMILLO-STAMETZ, PHARMD

srmp Atorvastatin Medical Valley

Drug Interactions Year 2 Clinical Pharmacology

STOPP and START criteria October 2011

Package leaflet: Information for the patient. Moventig 12.5 mg film-coated tablets Moventig 25 mg film-coated tablets. naloxegol

Prescribing and Pharmacokinetic Considerations in the Elderly

Pain Module. Top Ten Pain Safety Tips

If yes, continue to #2. If no, do not approve. DENIAL TEXT: See the initial denial text at the end of the guideline.

David Gardner, BSc Pharm, MSc CH&E, PharmD Professor, Department of Psychiatry & College of Pharmacy

Disclosure. Screening for adverse drug events: a tool to improve safe medication use

Why does percocet make you sleepy

Drug Screening. Separating Facts from Myths

IBRUTINIB (IMBRUVICA ) for Chronic Lymphocytic Leukaemia. and Mantel Cell Lymphoma

health care quality Your Medicine: Play It Safe Medicine Record Form at the Learn more about how to take medicines safely. Use the

Back to Basics: The Basics of Medication Monitoring

From medicines reconciliation to medicines review. Dr. Fatma Karapinar Hospital pharmacistepidemiologist

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Box, UAE Tel: Fax:

Determinants of potential drug drug interaction associated dispensing in community pharmacies in the Netherlands

Transcription:

Alert Fatigue with DDI Software: Potential Solutions John R. Horn, PharmD, FCCP Professor of Pharmacy School of Pharmacy and Associate Director of University of Washington Medical Center Pharmacy Department University of Washington Seattle, Washington

What is the Purpose of a Drug Interaction Screening Program? To identify potential interactions and initiate steps to prevent possible patient harm

Prediction Prediction is very difficult. Especially if it s about the future. Niels Bohr

Physicians and Computerized Drug Interaction Alerts 4751 First Data Bank DI alerts MDs tried to reenter same drug pair 26% of the time 3129 separate pairs: Override rate:» Level 1 (Serious / substantial evidence) 89.4%» Level 2 (Less serious) 96.3%» Level 3 (Serious / some evidence) 85.4% Weingart SN et al. Arch Intern Med.2004;163;2625-31.

Drug Interaction Severity: What is Severe? Evaluated alerts rated as contraindicated by CDS software Found that 50% of the alerts were not contraindicated in labeling Many contraindicated in label could be administered under appropriate monitoring Hatton et al. Ann Pharmacother 2011;45:297-308

Drug Interaction Severity: What is Severe? Common contraindicated alerts:» Ibuprofen Ketorolac» Glycopyrrolate etc KCL» Linezolid NE, Epi Common contraindicated alerts that are not:» Amiodarone Haloperidol» Linezolid Morphine, Fentanyl, Dextromethorphan» Amiodarone - Azithromycin Hatton et al. Ann Pharmacother 2011;45:297-308

Pennsylvania Patient Safety Advisory A 30-yr old patient was ordered Percocet (325 APAP and 5 mg oxycodone). The patient also was ordered Darvocet N-100 (650 mg APAP and 100 mg propoxyphene). APAP intake was 4550 mg and 5200 mg on the first 2 days. Safety comment: Computer did not notice excessive APAP dose. But, no mention of propoxyphene (3A4 and 2D6 inhibitor) PK and PD interaction with oxycodone (3A4 and 2D6 substrate) that computer did not note. Patient Safety Authority, 2007;4(Suppl 2):1

Drug Interactions in Croatia Patients taking 2 or more drugs during 2 days screened with computerized database (n=380) 46% of prescriptions involved at least one drugdrug interaction 6.2 drugs/pt and 2.8 DDIs/pt 33% Rated Severe; 56% Rated Moderate 45% Pharmacodynamic mechanism Erdeljic etal, Int J Clin Pcol Ther. 2010;48:821

Drug Interactions in Croatia Drug 1 Drug 2 % of INXs Severity Furosemide ACEI 6.3 Moderate Furosemide Corticosteroids 5.4 Moderate Theophylline Diuretic 4.2 Minor Digoxin Diuretic 4.2 Moderate ACEI KCL 4.0 Major LMWH Aspirin 3.3 Moderate Corticosteroids Fluconazole 2.9 Major LMWH NSAID 2.9 Moderate Theophylline H2-RA 2.7 Minor Erdeljic etal, Int J Clin Pcol Ther. 2010;48:821

Clinical Decision Support: Properties of an Ideal DDI Alerting System Sensitive and specific Clearly identified criteria for severity rating Customizable Summary of clinical data Management options provided Ignores discontinued meds / non-interacting formulations

Causes of Alert Fatigue Refills Discontinued prescriptions Low specificity for clinical significance Based on non-clinical data Desire to have complete listing Legal concerns

What To Do About Too Many DDI Alerts Turn off selected categories or remove really irritating alerts Do in-house review of DI database to revise existing alerts Outsource review of DI database to revise existing alerts

Alert Major-Contraindicated Only: What You Will NOT See Amiodarone Amitriptyline, Desipramine, Haloperidol Haloperidol Quinidine Conivaptan Ergots, Simvastatin, Lovastatin Ramelteon Fluvoxamine (190x inc AUC) Sirolimus Itra-, Ketoconazole, Clarithromycin, Ritonavir Ketoconazole Simvastatin, Lovastatin Dalfo-/Quinupristin Bepridil, Cisapride, Quinidine

Alert Level 1 Only: What You Will NOT See Saverno evaluated 64 DDI screening programs using 13 positive and 6 negative DDI pairs in patient profile of 18 drugs. (> 30 pddis) Median of correct responses = 89% (47 100%) Informatics listservers tested list. Missed these:» CBZ Clarithromycin» Digoxin Amiodarone, clarithromycin, itraconazole» Warfarin Amiodarone, gemfibrozil, naproxen Saverno KR et al. JAMIA. 2011;18:32-37.

What To Do About Too Many DDI Alerts Do in-house review of DI database» Advantage: Resources already there; can do by committee» Disadvantage: Resources; done by committee; available expertise? Outsource review of DI database» Advantage: Expertise, Resources» Disadvantage: Resources; Updating

In House Customized Computerized DDI Screening: Critical Interactions Theophylline Allopurinol, Febuxostat Gemfibrozil Simva, Lova, Atorvastatin Selegiline TCAs Atorvastatin, Lovastatin Telithromycin Irinotecan Ketoconazole (Fluconazole ok)

In House Customized Computerized DDI Screening: Critical Interactions CCBs (all) BBs (all) [due to AV block] Digoxin - Amiodarone, Macrolides (all), Quinidine, Verapamil, Tetracycline (But not azoles) Quinidine Amiodarone, Verapamil Warfarin Macrolides (all) Theophylline Allopurinol

Theophylline Allopurinol: A Major Drug Interaction Listed as major in several CDS databases, including institutionally customized Two studies found no change in theo PK with allopurinol 300 mg daily x 7 days. One study found approx 25% incr in AUC and half-life after 2 weeks of allopurinol 300 mg BID compared to the first dose of theophylline.

Theophylline Allopurinol: A Major Drug Interaction? Theophylline 35% 1A2 3-methylxanthine 1A2 16% 1-methylxanthine 40% 3A, 2E1 1,3 dimethyluric acid 1-methylurinc acid Xanthine Oxidase

What To Do About Too Many DDI Alerts Do in-house review of DI database» Advantage: Resources already there; can do by committee» Disadvantage: Resources; done by committee; available expertise? Outsource review of DI database» Advantage: Expertise, Resources» Disadvantage: Resources; Updating

Simplified CDS DDI Categories: Action Based on Risk Intervention Required» This drug combination is contraindicated. Review Required» A serious adverse outcome may occur. Interventions are necessary to reduce patient risk. Potential Interaction Identified» This interaction has been documented; however, the risk is modest or unclear.

Customized DI Screening In preparation for CPOE, customize DI database Start with DIs labeled as MAJOR About 8000 unique pairs in UWMC s database (2007) Each pair evaluated for appropriate classification in database (Major Moderate Minor) Horn JR et al. Am J Health-Syst Pharm. 2011;68:662-4.

Customized DDI Screening Evaluation criteria was probability of patient harm MAJOR should only include DDIs where risk likely to exceed benefit in most patients MAJOR DDIs should require thought and action Horn JR et al. Am J Health-Syst Pharm. 2011;68:662-4

Hospital Customized DDI Screening Total MAJORs in Database UWMC 7970 57 DIs Reduced in Severity (%) Hospital 2 8404 59 Hospital 3 11727 65 Hospital 4 12268 77 Hospital 5 15271 67

Customized CDS DDI Alerts Reviewed all DDI alerts over 24 hours (9/15/09) at HMC / UWMC 410 / 395 beds 400 / 336 occupied 25,697 / 29,671 alerts = 64 / 88 pt/day 505 / 617 were Major under our customized classification system

Computerized DDI Screening: Future Directions Improve the computer drug interaction screening systems knowledge base systems Consistent classification system for drug interactions probably will never happen Obtain additional epidemiological data User selectable choice in severity ratings

Drug Interaction to Avoid Never, under any circumstances, take a sleeping pill and a laxative on the same night.

Alert Fatigue with Drug-Drug Interaction Software: The Way Forward Andrew C. Seger, PharmD Senior Research Pharmacist Division of General Internal Medicine and Primary Care Clinical and Quality Analysis, Information Systems Partners HeatlhCare System June 22, 2011

Goals Develop understanding of how DDI alerting fails patients Think about how DDI alerting can be improved

Objectives Describe how DDIs work from an informatics perspective Understand potential DDI improvement strategies

What role does IT play?

To make no mistakes in not in the power of man; but to learn from their error and mistakes the wise and the good learn wisdom for the future. Plutarch (AD 46-120 AD)

Every day I write the book Clinical Providers Pharmacists Nurses Physicians Respiratory Therapists

From Singapore

Drug-Drug Interactions Clinical Decision Support (CDS) Why, they stink! Epidemiology Informatics

DDI: Informatics How they work CPOE perspective Similar in pharmacy systems, but different nomenclature? EMAR

DDI: Informatics 1 very large table (all meds) Behind it are other tables IF active drug a AND order for drug b, THEN show this alert

DDI: Informatics How many? Around 1.25 million pairs How to reduce? Expert committee Re-invents the DDI wheel

DDI: Informatics Other reduction strategies Tiering? Once again, committee Once again, re-invents DDI wheel

DDI: Informatics Other reduction strategies Patient s clinical state? How does this work? Aspirin-Warfarin example

Problems? DDI: Informatics Re-working all 1.25 million DDIs Shoveling out the stables Insert IS joke here More patient specific

DDI: Epidemiology Does not exist Currently all reports are anecdotal No rates There never will be!

DDI: Epidemiology Why Not? This is REALLY important for us to improve DDI functionality Ethics

DDI: Epidemiology No current surveillance Why not? MONEY, MONEY, MONEY Not just the mother s milk of politics

DDI: Epidemiology Back to square 1 Improvement of current alerting Is it possible? Example

DDI: Example Moxifloxacin Calcium Carbonate Magnesium Oxide Same Time (DDI) 2 hours later (Ø DDI)

DDI: Future Thoughts How to improve? Where should they alert? CPOE? Pharmacy OE? EMAR?

The true goal of patient safety efforts is to reduce the harm we do to our patients while providing them with the care they need recognizing the nature and sources of harm is critical to this endeavor Kilbridge PM, Classen DC Quality and Safety in Healthcare Vol 15 (3) June 2006